Available Now In The Library
Tirzepatide is an FDA-approved dual GIP and GLP-1 receptor agonist prescribed for type 2 diabetes and weight management; this page summarizes its label and research context for educational use only, not medical advice.
Selected: Standard Access
Educational use only — not medical advice. This guide summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.
Educational reference. This page does not publish dose ranges or reconstitution arithmetic.
Tirzepatide is a single 39-amino-acid synthetic peptide that activates two incretin receptors rather than one: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. It is based on the native GIP sequence, with modifications and a C20 fatty-diacid chain that promotes albumin binding and extends its duration of action to support weekly dosing. Through the GLP-1 receptor it is reported to enhance glucose-dependent insulin secretion, suppress glucagon and slow gastric emptying, as with a conventional GLP-1 agonist. The added GIP-receptor activity is the distinguishing feature: published research describes GIP agonism as contributing further effects on insulin secretion, adipose-tissue handling of nutrients, and central appetite regulation. This dual action is the reported explanation for the larger average weight reduction seen with tirzepatide than with single-agonist GLP-1 therapy in head-to-head trials.
In clinical trials tirzepatide has been associated with marked HbA1c reduction in type 2 diabetes and with the largest average weight reductions reported for an approved incretin therapy - the SURMOUNT-1 trial reported roughly 21% mean weight reduction at 72 weeks at the highest dose in people with obesity, and SURPASS-2 reported greater HbA1c and weight reduction than semaglutide 1 mg in a head-to-head comparison. It has also been reported to reduce apnea-hypopnea events in obstructive sleep apnea with obesity. These are reported trial findings in supervised populations, not guaranteed outcomes; individual results varied and weight regain after discontinuation has been reported. Nothing here is a promise of efficacy or a personal recommendation.
Dated milestones taken from the primary records: the molecule's discovery, its first registered human study, the trials that shaped the evidence and the regulatory decisions. Each entry links to the record it comes from.
Records checked Oct 3, 2026
The claims most often made about this compound, each with the strongest kind of evidence we found for it. The grade says what was studied, not whether the claim is true; the line beside it says what that study showed.
The reasoning behind each grade, study by study, is in this guide's Benefit & Outcome Review.
Grades checked Oct 5, 2026
A printable reference sheet with the compound's key facts, storage guidance and a vial record comes with All-Access Lifetime.
Tirzepatide has a plasma half-life of approximately 5 days (about 117 hours), supporting once-weekly dosing. Steady state is reached after roughly 4 weeks of consistent weekly administration, which aligns with the label's requirement to stay at a dose for at least 4 weeks before increasing - each step is assessed near steady state. The extended half-life means the drug persists for weeks after the last dose.
The most commonly reported adverse effects are gastrointestinal - nausea, diarrhoea, vomiting, constipation, abdominal pain and dyspepsia - which are dose-related and most frequent during escalation. The label carries a boxed warning for thyroid C-cell tumours based on rodent studies, and the label lists a personal or family history of medullary thyroid carcinoma or MEN 2 as a contraindication. Pancreatitis, gallbladder disease, acute kidney injury secondary to dehydration, hypersensitivity reactions and diabetic retinopathy complications have been reported, and hypoglycaemia risk rises when combined with insulin or sulfonylureas. Reduced efficacy of oral contraceptives after the first dose has also been noted in the label owing to delayed gastric emptying. This is a summary of reported label safety information, not an exhaustive profile, and nothing here is medical advice - these risks are among the reasons this is a supervised prescription medicine.
Primary sources include the FDA prescribing information for Mounjaro and Zepbound (dosing, half-life, boxed warning and contraindications) and the published trial programmes: SURPASS in type 2 diabetes, including the SURPASS-2 head-to-head comparison against semaglutide, and SURMOUNT in weight management, reported in the New England Journal of Medicine. Label details cited here reflect the FDA-approved labeling; readers should consult the current label, since approved indications and dosing are periodically updated.
Evidence File
Tirzepatide has one of the largest trial programmes in metabolic medicine, which makes an evidence file an audit rather than a search. This module reads the ClinicalTrials.gov record under all four names the compound is registered under, separates the trials that reported from the trials that quietly did not, and traces the figures that circulate in marketing copy back to the specific analysis that produced each one. It records the terminated, withdrawn and no-longer-updated studies in their sponsors' own words, reads the registry entries where the number everyone assumes exists is simply not written down, and shows one trial where the registry's posted result and the published paper's result for the same endpoint are not the same number. Every identifier here was fetched from a primary API on the verification date.
9 more sections in the Evidence File for Tirzepatide
Unlock the Evidence File, Sourcing File and Benefit & Outcome Review for Tirzepatide for $14 — or every compound in the library, plus the printable reference sheets, for $99.
The sections above this one stay free to read without an account.
Sourcing File
Tirzepatide is unusual among research-market peptides in having an FDA-approved twin, which means its true formula, mass and composition are published by a regulator rather than inferred. That turns a sourcing file into something a certificate can actually be measured against. This module assembles the reference values from three independent authorities, shows why one of the two exact masses in the public chemical record is not the one a mass spectrometer reports first, works the concentration arithmetic that a single missing line on a certificate quietly invalidates, and reads an illustrative certificate one row at a time to show what each line does and does not establish.
7 more sections in the Sourcing File for Tirzepatide
Unlock the Evidence File, Sourcing File and Benefit & Outcome Review for Tirzepatide for $14 — or every compound in the library, plus the printable reference sheets, for $99.
The sections above this one stay free to read without an account.
Benefit & Outcome Review
A compound with this much evidence behind it presents an unusual problem: almost every claim made for it has a real trial somewhere in its vicinity, which makes the vague claims harder to catch rather than easier. This review takes the statements that circulate most often, finds the specific analysis each one rests on, and grades it against what that analysis measured, in whom, for how long, and against what comparator. Several of the most repeated claims turn out to be contradicted by the sponsor's own data rather than merely unproven, and those are given the most space.
8 more sections in the Benefit & Outcome Review for Tirzepatide
Unlock the Evidence File, Sourcing File and Benefit & Outcome Review for Tirzepatide for $14 — or every compound in the library, plus the printable reference sheets, for $99.
The sections above this one stay free to read without an account.
Continue exploring related educational guide topics in the Medibact library.
Quick answers about guide scope, access, and educational use context.
Tirzepatide is a single peptide that activates both the GIP and GLP-1 receptors, approved by the FDA as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and for obstructive sleep apnea with obesity. The dual mechanism is the reported reason it produced larger average weight reduction than single-agonist GLP-1 therapy in head-to-head trials. It is a prescription medicine.
The label starts at 2.5 mg once weekly for 4 weeks as a tolerance-building dose, then increases in 2.5 mg steps after at least 4 weeks at the current dose. Recommended maintenance doses are 5 mg, 10 mg or 15 mg once weekly, chosen on response and tolerability - reaching 15 mg takes about 20 weeks. This is what the label specifies for supervised prescription use, not a recommendation for any individual.
Semaglutide activates the GLP-1 receptor only; tirzepatide activates both GIP and GLP-1 receptors. In the SURPASS-2 head-to-head trial tirzepatide produced greater HbA1c and weight reduction than semaglutide 1 mg. Their half-lives also differ - roughly 5 days for tirzepatide versus about 7 for semaglutide - and their dose scales are not comparable, so milligram figures cannot be carried across between them.
No. The figures shown describe the approved label and published trials for educational context. This page does not recommend a personal dose, route or frequency and is not medical advice. Tirzepatide is a prescription medicine with a boxed warning and real contraindications - any actual use should be directed and monitored by a qualified professional.
A certificate of analysis (COA) is a laboratory’s report on one sample of one batch. The single most useful thing to know about it is that purity and identity are two separate results that fail in different ways. A high purity figure says the sample was mostly one substance; it does not say that substance was Tirzepatide. Identity — normally a mass-spectrometry result matching the expected molecular weight — is what establishes what the material actually is, and a certificate reporting purity alone has not answered that question.
Two further limits are worth holding onto. Mass per vial is its own test: a vial can be 99% pure and still contain less material than the label claims. And sterility, endotoxin, heavy metals and residual solvent screening are separately commissioned tests, usually priced individually — so a “third-party tested” badge asserts none of them unless the certificate names them. Check that the batch or lot number on the document matches the vial in front of you; an unmatched certificate describes someone else’s material.
Tirzepatide also exists as an approved prescription medicine. A third-party certificate reports what was in the tested sample — it does not make research-market material equivalent to the approved product or its labelling, formulation and manufacturing controls.
Medibact does not test, endorse or resell peptides, and publishes no rating of any laboratory. How to read a peptide certificate of analysis walks through the document section by section, and what each COA field establishes covers the field-by-field detail and the laboratories that publish their methods.
You’ll need bacteriostatic water
Reconstitution is volume arithmetic — it assumes a lyophilized vial is dissolved in bacteriostatic water, which is sterile water preserved with 0.9% benzyl alcohol. The preservative is what allows a vial to be entered more than once; plain sterile water carries none and is single-entry by design. Medibact supplies USP-grade Bacteriostatic Water for Injection in a 30 mL multi-dose vial, produced in an FDA-registered U.S. facility and shipped from the United States, for research use only. One 30 mL vial covers 30 reconstitutions at 1 mL each, 15 at 2 mL, or 10 at 3 mL — division only, not a dosing recommendation.
New to reconstitution? Read how to reconstitute peptides or bacteriostatic water vs sterile water. Medibact does not sell peptides.
Educational use only — not medical advice. This guide summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.